Drug Trial Radar · NCT04972396
Pemvidutide (ALT-801) DDI Study in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jun 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Sep 15, 2021
Primary completion
May 15, 2022
Study completion May 15, 2022
Sponsor
- Lead sponsor
- Altimmune, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, open-label, drug-drug interaction (DDI) study of pemvidutide (ALT-801) under steady state conditions on concomitantly administered medications in healthy subjects. The study will evaluate the effect of pemvidutide on the pharmacokinetics (PK) of metformin, warfarin, atorvastatin, digoxin, and the combined oral contraceptive (COC) ethinylestradiol/levonorgestrel. The study will be conducted in 3 parts, as described below. Each part will have 2 periods in a fixed sequence, where the first period is without pemvidutide administration and the second is with pemvidutide at steady state.
Conditions
- NASH - Nonalcoholic Steatohepatitis
Interventions
PemvidutideDrug
Injected subcutaneously (SC)
MetforminDrug
Taken by mouth (PO)
AtorvastatinDrug
Taken by mouth (PO)
WarfarinDrug
Taken by mouth (PO)
DigoxinDrug
Taken by mouth (PO)
Ethinylestradiol and LevonorgestrelDrug
Taken by mouth (PO)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Plasma Concentration Versus Time Curve (AUC) of metformin and atorvastatin/warfarin and digoxin in presence of steady state ALT-801Time frame: Baseline and Day 36
- Area Under the Plasma Concentration Versus Time Curve (AUC) of ethinylestradiol and levonorgestrel in presence of steady state ALT-801Time frame: Baseline and Day 43
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Nucleus Network
Brisbane, Australia
CMAX Clinical Research
Adelaide, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.